Viking Therapeutics Investors Await Crucial Pipeline Update
31.01.2026 - 17:23:04
All eyes are on Viking Therapeutics as the biopharmaceutical firm prepares to release its latest financial results. The upcoming report for the fourth quarter and full year 2025, expected in the coming days, is seen less as a routine earnings event and more as a critical platform for detailing progress in its clinical pipeline. The primary focus for the market is the company's lead drug candidate, VK2735, being developed to treat obesity.
Investors and analysts are anticipating specific updates on several fronts when the company presents its figures, reportedly scheduled for Wednesday. The conference call accompanying the release is expected to provide a deeper operational outlook.
The central point of interest is the advancement of the VANQUISH Phase 3 program for the subcutaneous formulation of VK2735. Market participants are keen for concrete details on patient recruitment and the study timeline. Following the completion of enrollment for the VANQUISH-1 trial in November 2025, clarity on the status of VANQUISH-2 recruitment is a key demand.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Beyond the subcutaneous version, developments regarding an oral formulation of VK2735 will also be scrutinized. Furthermore, the update may include progress on other candidates in Viking's pipeline, such as VK2809 for non-alcoholic steatohepatitis (NASH).
Navigating a Competitive Landscape
This update arrives during a period of intense competition within the obesity therapeutics market, where several large pharmaceutical companies are active. For a smaller biopharma firm like Viking Therapeutics, robust clinical data and reliable development schedules have become essential differentiators. Consequently, the substance of the management's commentary on the VANQUISH studies and the broader VK2735 development path will likely carry more weight than the quarterly financial metrics themselves.
In summary, the investment community is looking for the upcoming report to deliver precise information on the late-stage trial progression for VK2735, offering tangible evidence of the program's momentum and future milestones.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from January 31 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 31.
Viking Therapeutics: Buy or sell? Read more here...
